Clinical trial
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for…
NCT00353457 · Abramson Cancer Center at Penn Medicine, Other · Terminated
Key facts
| NCT number | NCT00353457 |
|---|---|
| Title | Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma |
| Official title | Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma |
| Lead sponsor | Abramson Cancer Center at Penn Medicine, Other |
| Collaborators | Bristol-Myers Squibb Industry Roche Pharma AG |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rectal Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Capecitabine, Oxaliplatin and Cetuximab, Radiation |
| Enrollment | 6 |
| Start date | Feb 1, 2006 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Jul 18, 2006 |
| Last update posted | Apr 9, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: